Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenues:
Products, net	$ 100,448	$ 87,011
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember
Collaboration	$ 13,226
Total revenues	113,674	$ 87,011
Cost and expenses:
Cost of sales (excluding amortization of in-licensed rights)	12,622	12,063
Research and development	136,144	90,553
Selling, general and administrative	82,768	60,566
Amortization of in-licensed rights	166	216
Total cost and expenses	231,700	163,398
Operating loss	(118,026)	(76,387)
Other income (loss):
Gain from sale of Priority Review Voucher	108,069
Other expense, net	(7,420)	(172)
Total other income (loss)	100,649	(172)
Loss before income tax expense	(17,377)	(76,559)
Income tax expense	115	84
Net loss	(17,492)	(76,643)
Other comprehensive income:
Unrealized gains on investments, net of tax	574	118
Total other comprehensive income	574	118
Comprehensive loss	$ (16,918)	$ (76,525)
Net loss per share - basic and diluted	$ (0.23)	$ (1.07)
Weighted average number of shares of common stock used in computing basic and diluted net loss per share	76,432	71,731